BRAINTREE, Mass., Oct. 19, 2022 /PRNewswire/ -- Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada. Under the agreement, Braintree Laboratories, a leader in gastroenterology and an affiliate of Sebela Pharmaceuticals, will be responsible for clinical development, registration, marketing, and sales in the United States and Canada. Tegoprazan, a novel potassium-competitive acid-blocker (P-CAB), is currently approved and marketed in several territories, including South Korea and China.
Dr. Reddy’s Laboratories to commercialise novel molecule Tegoprazan in India
Domestic pharmaceutical companies are actively developing combination drugs, government data showed.
Market Place
Share
Tegoprazan News Full Screen View
Share
